These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 10533465)
1. Comments on: Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine, Seeber, et al., Eur J Cancer 1998, 34, 2129-2131. Comella P; Daponte A Eur J Cancer; 1999 Jul; 35(7):1163-4. PubMed ID: 10533465 [No Abstract] [Full Text] [Related]
2. Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma. Merimsky O; Chaitchik S Eur J Cancer; 1993; 29A(3):481-2. PubMed ID: 8398358 [No Abstract] [Full Text] [Related]
3. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Avril MF; Bonneterre J; Delaunay M; Grosshans E; Fumoleua P; Israel L; Bugat R; Namer M; Cupissol D; Kerbrat P Cancer Chemother Pharmacol; 1990; 27(2):81-4. PubMed ID: 2249337 [TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Seeber A; Binder M; Steiner A; Wolff K; Pehamberger H Eur J Cancer; 1998 Dec; 34(13):2129-31. PubMed ID: 10070323 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710 [TBL] [Abstract][Full Text] [Related]
6. Fotemustine and DTIC combination in patients with disseminated malignant melanoma. Merimsky O; Inbar M; Chaitchik S Am J Clin Oncol; 1992 Feb; 15(1):84-6. PubMed ID: 1550085 [TBL] [Abstract][Full Text] [Related]
7. Fotemustine plus dacarbazine for malignant melanoma. Avril MF; Bonneterre J; Cupissol D; Grob JJ; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D Eur J Cancer; 1992; 28A(11):1807-11. PubMed ID: 1389514 [TBL] [Abstract][Full Text] [Related]
8. Fotemustine plus dacarbazine in advanced stage III malignant melanoma. Binder M; Winkler A; Dorffner R; Glebowski E; Wolff K; Pehamberger H Eur J Cancer; 1992; 28A(11):1814-6. PubMed ID: 1389516 [TBL] [Abstract][Full Text] [Related]
9. Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine. Oliver V; Aliaga A; Lopez Lopez JJ; Perez E; Ponchon A; Bizzari JP; Cour V Eur J Cancer; 1993; 29A(2):287. PubMed ID: 8422299 [No Abstract] [Full Text] [Related]
10. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Roos WP; Quiros S; Krumm A; Merz S; Switzeny OJ; Christmann M; Loquai C; Kaina B Oncotarget; 2014 Dec; 5(24):12607-20. PubMed ID: 25557167 [TBL] [Abstract][Full Text] [Related]
11. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. Daponte A; Signoriello S; Maiorino L; Massidda B; Simeone E; Grimaldi AM; Caracò C; Palmieri G; Cossu A; Botti G; Petrillo A; Lastoria S; Cavalcanti E; Aprea P; Mozzillo N; Gallo C; Comella G; Ascierto PA; J Transl Med; 2013 Feb; 11():38. PubMed ID: 23402397 [TBL] [Abstract][Full Text] [Related]
12. Ipilimumab with fotemustine in metastatic melanoma. Garbe C Lancet Oncol; 2012 Sep; 13(9):851-2. PubMed ID: 22894885 [No Abstract] [Full Text] [Related]
13. Temozolomide in combination with fotemustine in patients with metastatic melanoma. Tas F; Camlica H; Topuz E Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803 [TBL] [Abstract][Full Text] [Related]
14. Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation. Petrović IM; Korićanac LB; Todorović DV; Ristić-Fira AM; Valastro LM; Privitera G; Cuttone G Ann N Y Acad Sci; 2007 Jan; 1095():154-64. PubMed ID: 17404028 [TBL] [Abstract][Full Text] [Related]
15. [Contribution of a new nitrosourea compound: fotemustine]. Boaziz C Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920 [TBL] [Abstract][Full Text] [Related]
16. Medical treatment and other combination regimens. Bajetta E; Del Vecchio M; Bajetta R; Canova S Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485 [No Abstract] [Full Text] [Related]
17. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity. Aamdal S; Gerard B; Bohman T; D'Incalci M Eur J Cancer; 1992; 28(2-3):447-50. PubMed ID: 1591062 [TBL] [Abstract][Full Text] [Related]
18. [New toxicity of fotemustine: diffuse interstitial lung disease]. Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481 [TBL] [Abstract][Full Text] [Related]
19. High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. Guida M; Cramarossa A; Fistola E; Porcelli M; Giudice G; Lubello K; Colucci G J Transl Med; 2010 Nov; 8():115. PubMed ID: 21067582 [No Abstract] [Full Text] [Related]
20. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]